Bevacizumab
This presentation is the property of its rightful owner.
Sponsored Links
1 / 19

Swiss Group for Clinical Cancer Reseach PowerPoint PPT Presentation


  • 94 Views
  • Uploaded on
  • Presentation posted in: General

Bevacizumab continuation versus no continuation after first-line chemo - bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial.

Download Presentation

Swiss Group for Clinical Cancer Reseach

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Swiss group for clinical cancer reseach

Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial

Koeberle D, Betticher D, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Frueh M, Kueng M, Popescu R, Schacher S, Hess V, Herrmann R

Swiss Group for Clinical Cancer Reseach


Background

Background

  • Chemotherapy plus Bevacizumab (BEV) is a standard option for first-line treatment in patients with metastatic colorectal cancer

  • In many countries duration of first line chemotherapy in the absence of disease progression or severe toxicity is usually limited to 4-6 months

  • After stopping first-line chemotherapy plus BEV the value of BEV monotherapy as maintenance strategy until disease progression is unknown


Study design

Study design

BEV continuation

(7.5 mg/kg q 3 w)

until PD

No PD

First-linechemo-therapy + BEV

for 4-6 months

Randomization

1: 1

No antitumor treatment

(no BEV) until PD

  • Stratification factors:

  • Best response during first-line chemotherapy + BEV (CR/PR vs SD)

  • Duration of first-line chemotherapy + BEV (16-20 vs 21-24 weeks)

  • Type of chemotherapy (Irinotecan + 5-FU vs Oxalipaltin + 5-FU vs

  • Fluoropyrimidine mono)

  • Disease burden (metastases in one organ vs multiple organs)

  • Center

  • Study conducted in 26 sites in Switzerland (accrual period 2007-2012)


Main eligibility criteria

Main eligibility criteria

  • Patients ≥ 18 years with pathologically confirmed diagnosis of colorectal adenocarcinoma

  • First-line chemotherapy for metastatic disease with oral or intravenous fluoropyrimidine alone, or in combination with irinotecan or oxaliplatin

  • Chemotherapy must have been given in combination with standard dose of BEV for at least 16, but no longer than 24 weeks as part of the first-line treatment

  • Last administration of BEV within 4 weeks before randomization

  • Stable disease (SD), partial response (PR) or complete response (CR) after end of chemotherapy/BEV first-line treatment (tumor assessment within 21 days before randomization)


Endpoints

Endpoints

Primary endpoint:

  • Time to progression (TTP)

    • Measured by CT-scans q 6 weeks from randomization until PD

      Secondary endpoints:

  • Progression freesurvival (PFS)

  • Time tosecond-linetreatment

  • Overall survival (OS)

  • Adverseeventsrelatedto BEV

  • Treatment costs


Statistical considerations

Statistical considerations

  • Non-inferiority study

    • Assumption: TTP of ≤ 22 weeks for BEV continuation TTP of ≥16 weeks for no BEV

    • Hypothesis: BEV vs. no BEV Hazard Ratio (HR) HR ≥ 16/22 = 0.727

  • 219 events required for a significance level of 10%, a power of 85% to detect a HR=1, one interim analysis

  • Analysis based on 262 evaluable patients (131 in each arm)


Patient characteristics

Patient characteristics


Results

Based on a median follow-up time of 30.1 months

(Range in living patients 2.7 - 54.9)

RESULTS


Ttp from randomization

TTP (from randomization)


Ttp subgroup analysis

TTP subgroup analysis


Pfs from start of first line therapy

PFS (from start of first-line therapy)


Time to second line treatment from randomization

Time to second-line treatment (from randomization)


Overall survival from start of first line therapy

Overall Survival (from start of first-line therapy)


Adverse events

Adverse events


Cost analysis

Cost analysis

Not included costs: Laboratory tests, out-patient AE treatments,

other out-patient treatments/care

1) Swiss prices and Swiss health system


Cost analysis1

Cost analysis

BEV

NO BEV


Cost analysis2

Cost analysis

Total costs USD


Summary

Summary

  • Non-inferiority could not be demonstrated

  • The difference in median TTP between BEV continuation versus no treatment after randomization is 5 weeks

  • Overall survival in both arms is not significantly different

  • Utility of BEV continuation needs to be balanced

    with significantly higher treatment costs


Acknowledgements

Acknowledgements

  • Patients

  • Investigators, study coordinators and nurses at SAKK coordination center and study sites

    Swiss Association of Social Health Insurance Companies

    Swiss Group for

    Clinical Cancer Research


  • Login